Health-care venture capital firm Longitude Capital has rounded up its largest fund yet after having a string of portfolio companies go public or be acquired, raising $585 million to invest in biotechnology and other medical startups.

"The Longitude Venture Partners IV (LVP4) will build on the proven strategy of its predecessor funds by investing in biotechnology,